hweb,
I am trying to set up a call with management.
My questions center around treatment revenue, as this seems so pivotal to EPS increases.(with the incremental margin over 10 million being so high) Mainly wondering whether recent revenue of 12.5 million and next q are just pent-up DOE budget that is being spent and then we go back down next year. Or there has there truly been a sea-change in DOE attitude??
I don't understand their cost structure on the services side as to whether it has good Op Lev' or whether it will be permanently a low margin business. Not interested in their new technology because I invest based on nows rather than maybes (JBII taught them that)
I also have doubts about management's ability, but a good sustainable EPS rise will be enough for me. I just can't get a read on whether it spikes for two quarters and then drops. If treatment revenue dops down, we swing back to pretty dramatic losses and the services side won't make up for it.
The lack of market reaction might suggest skepticism, or is truly misunderstood/undiscovered?
Please email me any questions you would like me to ask them.
sbsji at yahoo.com
